News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
323,878 Results
Type
Article (19346)
Company Profile (124)
Press Release (304408)
Section
Business (104939)
Career Advice (857)
Deals (18470)
Drug Delivery (83)
Drug Development (50489)
Employer Resources (79)
FDA (7570)
Job Trends (7700)
News (184925)
Policy (17259)
Tag
Academia (725)
Africa (407)
Alliances (27606)
Alzheimer's disease (519)
Antibody-drug conjugate (ADC) (39)
Approvals (7536)
Arizona (45)
Artificial intelligence (52)
Asia (24226)
Australia (3108)
Bankruptcy (170)
Best Places to Work (5343)
Biosimilars (57)
Biotechnology (57)
C2C Services and Suppliers (13097)
California (817)
Canada (526)
Cancer (217)
Cardiovascular disease (33)
Career advice (694)
Cell therapy (38)
China (78)
Clinical research (41020)
Collaboration (75)
COVID-19 (1047)
Cystic fibrosis (41)
Data (134)
Diabetes (50)
Diagnostics (1664)
Drug pricing (73)
Earnings (37682)
Employer resources (71)
Europe (49832)
Events (46778)
Executive appointments (90)
FDA (7661)
Florida (107)
Funding (51)
Gene therapy (56)
GLP-1 (422)
Government (1767)
Healthcare (5826)
Hotbed/Location (218889)
Illinois (91)
Indiana (77)
Infectious disease (1065)
Inflammatory bowel disease (58)
Interviews (113)
IPO (7240)
IRA (31)
Job creations (2424)
Job search strategy (642)
Kansas (54)
Layoffs (241)
Legal (4058)
Lung cancer (56)
Manufacturing (62)
Maryland (125)
Massachusetts (702)
Medical device (1927)
Medtech (1930)
Mergers & acquisitions (11145)
Metabolic disorders (210)
Minnesota (60)
Neuroscience (606)
New Jersey (329)
New York (252)
NextGen Class of 2024 (2340)
Non-profit (898)
North Carolina (285)
Northern California (377)
Obesity (135)
Ohio (46)
Opinion (166)
Patents (53)
Pennsylvania (234)
People (32602)
Pharmaceutical (63)
Phase I (12738)
Phase II (17375)
Phase III (14002)
Pipeline (70)
Podcasts (48)
Policy (52)
Postmarket research (1608)
Preclinical (4473)
Rare diseases (83)
Real estate (3158)
Regulatory (11907)
Research institute (814)
Resumes & cover letters (138)
South America (600)
Southern California (339)
Startups (2003)
Texas (96)
The Weekly (31)
United States (3602)
Vaccines (169)
Washington State (95)
Weight loss (137)
Date
Today (61)
Last 7 days (311)
Last 30 days (1113)
Last 365 days (18615)
2024 (12794)
2023 (19635)
2022 (25867)
2021 (26642)
2020 (24872)
2019 (20058)
2018 (15587)
2017 (17255)
2016 (16203)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12739)
323,878 Results for "aurobindo pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
Business
FSD Pharma provides Corporate Update
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.
June 28, 2024
·
10 min read
FDA
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
June 26, 2024
·
10 min read
Outcome of Innate Pharma’s 2024 Annual General Meeting
Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 23, 2024, in Marseille.
May 23, 2024
·
3 min read
Pharmacy benefit managers
PBM Execs Point Fingers at Pharma Industry in House Hearing on Rising Drug Prices
Executives from the three largest pharmacy benefit manager companies testified Tuesday before Congress that rising drug prices in the U.S. are due to pharma companies taking advantage of market exclusivities and excessive charges.
July 24, 2024
·
2 min read
·
Tristan Manalac
Altus Formulation and Spektar Join Forces in New Specialty Company Spektus Pharma
Spektar Therapeutics FZCO and Altus Formulation Inc. announced the launch of Spektus Pharma Inc. a new Canadian specialty pharma company developing patent-protected value-added medicines for the growing CNS segment.
June 18, 2024
·
2 min read
Drug Development
NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial
NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.
May 28, 2024
·
2 min read
·
Tristan Manalac
1 of 32,388
Next
